SCHEMBL4150006

SCHEMBL4150006

COc1ccc(CN(C(=O)c2c(F)cccc2F)C(=O)N(C)c2ccc(SC(F)(F)F)cc2F)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LPAR1 Q92633 2/20 0.36
LPAR5 Q9H1C0 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDK1 Q15118 1/20 0.36
HSD17B2 P37059 1/20 0.36
BCL2A1 Q16548 2/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
HSP90AA1 P07900 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
GAA P10253 2/20 0.34
HPGD P15428 1/20 0.34
MAPT P10636 1/20 0.34
TP53 P04637 1/20 0.34
ACHE P22303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4166881 0.92 MEN1 (0.41) MEN1KMT2ALPAR1LPAR5ALDH1A1
SCHEMBL4159030 0.89 TDP1 (0.45) MEN1KMT2AALDH1A1TSHRMAPK1
SCHEMBL4158131 0.84 RORC (0.33) TSHRMAPK1TDP1MAPT
SCHEMBL4166771 0.84 RXFP1 (0.36) MEN1KMT2AGAAHPGDMAPT
SCHEMBL4157996 0.83 RORC (0.35) TSHRMAPK1TDP1MAPT
SCHEMBL4145173 0.83 GPBAR1 (0.33) SMN1; SMN2TDP1MAPT
SCHEMBL4157502 0.83 MLYCD (0.35) TDP1
SCHEMBL4158385 0.83 CYP3A4 (0.43) KMT2AALDH1A1PDK1MAPTTP53
SCHEMBL4142662 0.82 RORC (0.34) TSHRMAPK1TDP1MAPT
SCHEMBL13774523 0.82 RORC (0.32) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176786-A1 Benzoylurea Compounds and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-07-09 US disclosed
US-20090176786-A1 Benzoylurea Compounds and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-07-09 US disclosed
US-20090176786-A1 Benzoylurea Compounds and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-07-09 US disclosed
EP-1937629-A2 BENZOYLUREA COMPOUNDS AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-07-02 EP disclosed
WO-2007046513-A2 BENZOYLUREA COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-04-26 WO disclosed
WO-2007046513-A2 BENZOYLUREA COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176786-A1 Benzoylurea Compounds and Use Thereof BTK, BRIX1, NFXL1 MEN1 1863/4885KMT2A 738/4885LPAR1 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.